ESTROGEN-RECEPTOR EXPRESSION IN HUMAN PITUITARY - CORRELATION WITH IMMUNOHISTOCHEMISTRY IN NORMAL TISSUE, AND IMMUNOHISTOCHEMISTRY AND MORPHOLOGY IN MACROADENOMAS
ESTROGEN-RECEPTOR EXPRESSION IN HUMAN PITUITARY - CORRELATION WITH IMMUNOHISTOCHEMISTRY IN NORMAL TISSUE, AND IMMUNOHISTOCHEMISTRY AND MORPHOLOGY IN MACROADENOMAS
复制标题
DOI：
10.1210/jcem.78.6.7515390
复制
发表时间：
1994-06-01
影响因子：
5.8
通讯作者：
SHUPNIK, MA
中科院分区：
文献类型：
--
作者：
FRIEND, KE;CHIOU, YK;SHUPNIK, MA
使用核糖核酸酶保护测定、[H-3]雌二醇 ([H-3]E(2)) 结合和 ER 免疫组织化学相结合的方法，检查 41 份人垂体腺瘤标本中是否存在雌激素受体 (ER) 信使核糖核酸和蛋白质。 ER 信使核糖核酸的患病率在 PRL 免疫反应性肿瘤中较高（2 个中的 2 个），在 GH/PRL 肿瘤中中等（5 个中的 2 个），在 GH 肿瘤中较低或不存在（4 个中的 0 个）。在 GH/PRL 免疫染色肿瘤中，ER 的存在一致与血清 PRL 水平升高相关。在促性腺激素免疫染色肿瘤中，17 个肿瘤中有 10 个呈 ER 阳性；在该组中，具有促性腺激素腺瘤特征的患者为 ER 阳性，而具有空细胞/嗜酸细胞特征的患者为 ER 阴性。在未对任何已知垂体前叶激素进行免疫染色的肿瘤中，11 个中有 3 个呈 ER 阳性。 14 个肿瘤中的 ER 免疫组织化学显示与核糖核酸酶保护测定结果有 100% 相关性，而在 9 个肿瘤中测定的 [H-3]E(2) 结合显示出 87% 相关性。总之，PRL 和一类特定的促性腺激素免疫染色肿瘤（可通过电子显微镜上的特定特征识别）含有 ER，而 GH 免疫染色肿瘤则为 ER 阴性。正常垂体中的 ER 表达与大腺瘤中的表达相似（GH，2.3%；PRL，50%；FSH，70%；LH，83%；TSH，4%；ACTH，1%）。 ER 阳性肿瘤代表一个子集，其生长和分泌特征可能受到性腺类固醇环境或影响 E(2) 水平或 ER 功能的药物的影响。
Forty-one human pituitary adenoma specimens were examined for the presence of estrogen receptor (ER) messenger ribonucleic acid and protein using a combination of ribonuclease protection assay, [H-3] estradiol ([H-3]E(2)) binding, and ER immunohistochemistry. ER messenger ribonucleic acid prevalence was high in PRL-immunoreactive tumors (2 of 2), moderate in GH/PRL tumors (2 of 5), and low or absent (0 of 4) in GH tumors. In the GH/PRL-immunostaining tumors, the presence of the ER was uniformly associated with elevated serum PRL levels. Among the gonadotropin-immunostaining tumors, 10 of 17 were ER positive; within this group, those with gonadotroph adenoma characteristics were ER positive, whereas those with null cell/oncocytic characteristics were ER negative. Of the tumors that did not immunostain for any known anterior pituitary hormones, 3 of 11 were ER positive. ER immunohistochemistry in 14 tumors revealed a 100% correlation with ribonuclease protection assay results, whereas [H-3]E(2) binding, determined in 9 tumors, showed an 87% correlation. In summary, it appears that PRL and a specific class of gonadotropin-immunostaining tumors (identifiable by specific characteristics on electron microscope) contain ER, whereas GH-immunostaining tumors are ER negative. ER expression in normal pituitary paralleled that in macroadenomas (GH, 2.3%; PRL, 50%; FSH, 70%; LH, 83%; TSH, 4%; ACTH, 1%). The ER-positive tumors represent a subset whose growth and secretory profiles may be influenced by the gonadal steroidal milieu or by pharmacological agents that affect E(2) levels or ER function.